ArticlePharmacoepidemiology and drug safety2025
Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Validation of an AI-Assisted Framework for Systematic Bias Assessment in Observational Studies.Journal of evaluation in clinical practice · 2026Article
- Distribution ofFrontiers in genetics · 2026Article
- Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study.Pharmacoepidemiology and drug safety · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeClopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial. This study investigates whether co-prescribing clopidogrel with PPIs is associated with a higher incidence of major adverse cardiovascular events (MACEs) compared to clopidogrel monotherapy.
methodsWe conducted a retrospective cohort study analyzing data from the Real-world Evidence Research Network in Saudi Arabia from 2016 to 2023. Patients were followed from their initial clopidogrel prescription until the occurrence of MACEs or the end of follow-up. We employed stabilized inverse probability of treatment weighting (SIPTW) to adjust for potential confounders and the Cox proportional hazards model to assess risks.
resultsA total of 29 572 patients were included, with 21 480 in the clopidogrel + PPI group and 8092 in the clopidogrel-only group. Baseline characteristics were balanced post SIPTW, with similar mean ages (clopidogrel + PPI: 65.9 years; clopidogrel only: 66.1 years) and 64% male representation. The incidence rate of MACE was 3.22 versus 2.92 per 10 000 person-days in the clopidogrel + PPI and clopidogrel-only groups, respectively. The weighted hazard ratio for MACE was 1.20 (95% CI, 1.01-1.43).
conclusionsIn this large real-world cohort study, we observed a modest but statistically significant increase in the risk of MACEs among patients who received concomitant clopidogrel and proton pump inhibitor therapy. Given the widespread use of these medications, these findings emphasize the need for individualized risk assessments when co-prescribing PPIs and clopidogrel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.